Davis Polk advised the joint book-running managers and representatives of the underwriters in the $200 million public offering by BeiGene, Ltd. of 6,250,000 American Depositary Shares, of which 5,781,250 ADSs were issued and sold by BeiGene and 468,750 ADSs were sold by certain selling shareholders. The ADSs are listed on the NASDAQ Global Select Market under the symbol “BGNE.”
BeiGene is a global, clinical-stage, research-based biotechnology company focused on targeted and immuno-oncological therapeutics.
The Davis Polk corporate team included partner Bruce K. Dallas and associates Jeannette K. Safi and Skawenniio Barnes. Partner John D. Paton and associate Omer Harel provided tax advice. The intellectual property and technology team included partner Pritesh P. Shah and associate Paul S. Lee. Counsel Marcie A. Goldstein provided FINRA advice. Members of the Davis Polk team are based in the Northern California, New York and London offices.